This is the list of Schedule III drugs as defined by the United StatesControlled Substances Act at 21 U.S.C.§ 812(c) and 21 C.F.R.1308.13, with modifications through August 22, 2014 (79 FR49961). The following findings are required for drugs to be placed in this schedule:[1]
- The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
The complete list of Schedule III drugs follows. The Administrative Controlled Substances Code Number for each drug is included.
Stimulants[edit]
ACSCN | Drug |
---|---|
1405 | See 21 CFR1308.13(b)(1) |
1228 | Benzphetamine |
1645 | Chlorphentermine |
1647 | Clortermine |
1615 | Phendimetrazine |
Depressants[edit]
List Of Class 2 Drugs
ACSCN | Drug |
---|---|
2126 | Amobarbital |
2100 | Any derivative of Barbituric acid |
2510 | Chlorhexadol |
2020 | Embutramide |
2012 | Xyrem (sodium oxybate) oral solution[2] |
2261 | Perampanel[3] |
7285 | Ketamine |
2575 | Methyprylon |
2600 | Sulfondiethylmethane |
2605 | Sulfonethylmethane |
2610 | Sulfonmethane |
7295 | Tiletamine and zolazepam |
7369 | Dronabinol in sesame oil and encapsulated in a soft gelatin capsule |
Others[edit]
ACSCN | Drug |
---|---|
9400 | Nalorphine |
Narcotics[edit]
ACSCN | Drug |
---|---|
9803 | Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium |
9804 | Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9807 | Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts |
9808 | Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9809 | Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9810 | Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts |
9064 | Buprenorphine |
Steroids[edit]
ACSCN | Drug |
---|---|
4000 | Anabolic steroids |
Hallucinogens[edit]
ACSCN | Drug |
---|---|
7300 | Lysergic acid |
7310 | Lysergic acid amide |
References[edit]
- ^21 U.S.C.§ 812(b)(3) retrieved September 3, 2014
- ^'Xyrem® (sodium oxybate) Oral Solution CIII. Prescribing information. Revised: December 2012'(PDF). Archived from the original(PDF) on 2013-02-03.
- ^'Department of Justice. Drug Enforcement Administration. Schedules of Controlled Substances: Placement of Perampanel into Schedule III'(PDF). Federal Register. Office of the Federal Register, National Archives and Records Administration. 78 (204): 62500–62506. October 22, 2013. Retrieved 22 February 2014.
This is the list of Schedule I drugs as defined by the United StatesControlled Substances Act.[1] The following findings are required for drugs to be placed in this schedule:[2]
- The drug or other substance has a high potential for abuse.
- The drug or other substance has no currently accepted medical use in treatment in the United States.
- There is a lack of accepted safety for use of the drug or other substance under medical supervision.
Except as specifically authorized, it is illegal for any person:
- to manufacture, distribute, or dispense, or possess with intent to manufacture, distribute, or dispense, a controlled substance; or
- to create, distribute, or dispense, or possess with intent to distribute or dispense, a counterfeit substance.[3]
The complete list of Schedule I drugs follows.[1] The Administrative Controlled Substances Code Number for each drug is included.
Opioids[edit]
ACSCN | Drug |
---|---|
9815 | Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide) |
9601 | Acetylmethadol |
9602 | Allylprodine |
9603 | Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM) |
9604 | Alphameprodine |
9605 | Alphamethadol |
9814 | Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) |
9832 | Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- piperidinyl]-N-phenylpropanamide) |
9606 | Benzethidine |
9607 | Betacetylmethadol |
9830 | Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N-phenylpropanamide) |
9831 | Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2- phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide |
9608 | Betameprodine |
9609 | Betamethadol |
9611 | Betaprodine |
9612 | Clonitazene |
9613 | Dextromoramide |
9615 | Diampromide |
9616 | Diethylthiambutene |
9168 | Difenoxin |
9617 | Dimenoxadol |
9618 | Dimepheptanol |
9619 | Dimethylthiambutene |
9621 | Dioxaphetyl butyrate |
9622 | Dipipanone |
9623 | Ethylmethylthiambutene |
9624 | Etonitazene |
9625 | Etoxeridine |
9626 | Furethidine |
9627 | Hydroxypethidine |
9628 | Ketobemidone |
9629 | Levomoramide |
9631 | Levophenacylmorphan |
9813 | 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide) |
9833 | 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) |
9632 | Morpheridine |
9661 | MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) |
9633 | Noracymethadol |
9634 | Norlevorphanol |
9635 | Normethadone |
9636 | Norpipanone |
9812 | Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide |
9663 | PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine |
9637 | Phenadoxone |
9638 | Phenampromide |
9647 | Phenomorphan |
9641 | Phenoperidine |
9642 | Piritramide |
9643 | Proheptazine |
9644 | Properidine |
9649 | Propiram |
9645 | Racemoramide |
9835 | Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide |
9750 | Tilidine |
9646 | Trimeperidine |
9821 | Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)[4] |
Opium derivatives[edit]
ACSCN | Drug |
---|---|
9319 | Acetorphine |
9051 | Acetyldihydrocodeine |
9052 | Benzylmorphine |
9070 | Codeine methylbromide |
9053 | Codeine-N-Oxide |
9054 | Cyprenorphine |
9055 | Desomorphine |
9145 | Dihydromorphine |
9335 | Drotebanol |
9056 | Etorphine (except hydrochloride salt) |
9200 | Heroin (diacetylmorphine) |
9301 | Hydromorphinol |
9302 | Methyldesorphine |
9304 | Methyldihydromorphine |
9305 | Morphine methylbromide |
9306 | Morphine methylsulfonate |
9307 | Morphine-N-Oxide |
9308 | Myrophine |
9309 | Nicocodeine |
9312 | Nicomorphine |
9313 | Normorphine |
9314 | Pholcodine |
9315 | Thebacon |
Hallucinogenic or psychedelic substances[edit]
ACSCN | Drug |
---|---|
7249 | Alpha-Ethyltryptamine (αET) |
7391 | 4-bromo-2,5-dimethoxy-amphetamine (DOB) |
7392 | 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) |
7396 | 2,5-dimethoxyamphetamine (DOA) |
7399 | 2,5-Dimethoxy-4-ethylamphetamine (DOE) |
7348 | 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts and salts of isomers |
7411 | 4-methoxyamphetamine (PMA) |
7401 | 5-methoxy-3,4-methylenedioxyamphetamine (MMDA) |
7395 | 4-methyl-2,5-dimethoxyamphetamine (DOM; STP) |
7400 | 3,4-methylenedioxyamphetamine (MDA, Sassafrass) |
7405 | 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Molly) |
7404 | 3,4-methylenedioxy-N-ethylamphetamine (MDEA; MDE) |
7402 | N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy MDA) |
7390 | 3,4,5-trimethoxyamphetamine (TMA) |
7431 | 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT) |
7432 | Alpha-methyltryptamine (αMT) |
7433 | Bufotenine |
7434 | Diethyltryptamine (DET) |
7435 | Dimethyltryptamine (DMT) |
7439 | 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts and salts of isomers |
7260 | Ibogaine |
7315 | Lysergic acid diethylamide (LSD) |
7360 | Marijuana or hemp, including cannabis resin |
7350 | Marijuana extracts; hemp extracts; cannabinoids[5] |
7381 | Mescaline |
7374 | Parahexyl |
7415 | Peyote |
7482 | N-ethyl-3-piperidyl benzilate |
7484 | N-methyl-3-piperidyl benzilate |
7437 | Psilocybin |
7438 | Psilocin |
7370 | Tetrahydrocannabinol (THC) |
7455 | Ethylamine analog of phencyclidine (Eticyclidine; PCE) |
7458 | Pyrrolidine analog of phencyclidine (PCPy) |
7470 | Thiophene analog of phencyclidine (TCP) |
7473 | 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (TCPy) |
1248 | 4-methylmethcathinone (Mephedrone) |
7535 | 3,4-methylenedioxypyrovalerone (MDPV) |
7509 | 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) |
7508 | 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) |
7519 | 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) |
7518 | 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) |
7385 | 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) |
7532 | 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) |
7517 | 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) |
7521 | 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) |
7524 | 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) |
7540 | 3,4-Methylenedioxy-N-methylcathinone (Methylone) |
Depressants[edit]
ACSCN | Drug |
---|---|
2010 | gamma-Hydroxybutyric acid (GHB; sodium oxybate; sodium oxybutyrate) except formulations in an FDA-approved drug product are Schedule III |
2572 | Mecloqualone |
2565 | Methaqualone |
Stimulants[edit]
ACSCN | Drug |
---|---|
1585 | Aminorex (aminoxaphen; 2-amino-5-phenyl-2- oxazoline; or 4,5-dihydro-5-phenly-2-oxazolamine) |
7493 | N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine), its optical isomers, salts and salts of isomers |
1235 | Cathinone |
1503 | Fenethylline |
1237 | Methcathinone (Some other names: 2-(methylamino)-propiophenone; alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432), its salts, optical isomers and salts of optical isomers |
1590 | (+/-)cis-4-methylaminorex |
1475 | N-ethylamphetamine |
1480 | N,N-dimethylamphetamine (also known as N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine) |
Cannabimimetic agents[edit]
ACSCN | Drug |
---|---|
7297 | 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497) |
7298 | 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) |
7118 | 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) |
7173 | 1-butyl-3-(1-naphthoyl)indole (JWH-073) |
7019 | 1-hexyl-3-(1-naphthoyl)indole (JWH-019) |
7200 | 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) |
6250 | 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) |
7081 | 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) |
7122 | 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) |
7398 | 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) |
7201 | 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201) |
7694 | 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) |
7104 | 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4) |
7008 | 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole 7008 (SR-18 and RCS-8) |
7203 | 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) |
Temporary/emergency listings[edit]
These items are listed by the Secretary of Health and Human Services pursuant to 21 CFR 1308.49.[6][7]
ACSCN | Drug |
---|---|
7144 | (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts and salts of isomers (UR-144, 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole) |
7011 | [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts and salts of isomers (5-fluoro-UR-144, 5-F-UR-144, XLR-11, 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole) |
7048 | N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (APINACA, AKB-48) |
7222 | Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (QUPIC, PB-22)[8] |
7225 | Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22)[8] |
7012 | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA)[8] |
7035 | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA)[8] |
7031 | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA)[9] |
7023 | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)[9] |
7024 | [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201)[9] |
7538 | 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)[10] |
7537 | 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)[10] |
7536 | 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)[10] |
9547 | 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]N-methylbenzamide) (U-47700)[11] |
9821 | Acetylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)[12] |
9834 | N-(1-Phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl fentanyl)[13] |
7034 | 2-(1-(5-Fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-ADB, 5F-MDMB-PINACA)[14] |
7033 | Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB)[14] |
7049 | N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA, 5F-AKB48)[14] |
7010 | N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA)[14] |
7042 | Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA, MMB-CHMINACA)[14] |
7020 | Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-FUBINACA)[14] |
9811 | Acryl fentanyl ((N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide); Acryloylfentanyl)[15] |
9816 | N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (Ortho-fluorofentanyl or 2-fluorofentanyl)[16] |
9822 | Butyryl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide)[17] |
9824 | 4-Fluoroisobutyryl fentanyl ((N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) or Para-fluoroisobutyryl fentanyl)[18] |
9825 | 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (Methoxyacetyl fentanyl)[16] |
9836 | Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide, N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide)[17] |
9843 | N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (Tetrahydrofuranyl fentanyl)[16] |
9845 | (1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (cyclopropyl fentanyl)[19] |
7032 | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA)[20] |
9840 | N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl)[21] |
9823 | N-(4-fluorophenyl)N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl fentanyl)[21] |
9837 | N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-methoxybutyryl fentanyl)[21] |
9826 | N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (para-chloroisobutyryl fentanyl)[21] |
9827 | N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl)[21] |
9847 | N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl fentanyl)[21] |
9838 | N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil)[21] |
9850 | Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers[22] |
References[edit]
- ^ ab21 CFR1308.11 (CSA Sched I) with changes through 77 FR64032 (Oct 18, 2012). Retrieved September 6, 2013.
- ^21 U.S.C.§ 812(b)(1)United States Code via Cornell University's Legal Information Institute. Retrieved on 2007-10-02.
- ^Drug Enforcement Administration (DEA) (22 Jan 2002). 'Title 21 — Food and Drugs Chapter 13 - Drug Abuse Prevention and Control Subchapter I — Control and Enforcement Part D — Offenses and Penalties: Sec. 841. Prohibited Acts A(a)'. Retrieved 23 Oct 2009.
- ^Drug Enforcement Administration, Department of Justice (2017). 'Schedules of Controlled Substances: Placement of Acetyl Fentanyl into Schedule I. Final order'. Federal Register. 82 (108): 26349–51. PMID28591974.
- ^https://www.gpo.gov/fdsys/pkg/FR-2016-12-14/pdf/2016-29941.pdf
- ^Code of Federal Regulations, 2012-04-01
- ^The first 8 items in the temporary section of the schedule shown on the DEA website are not included here because they are duplicates of entries in the tables above. Presumably, this is because they were made permanent and copied there at some point, but inadvertently not deleted from this temporary listing section.
- ^ abcdDrug Enforcement Administration, Department of Justice (Feb 10, 2014). 'Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order'. Fed. Regist. 79 (27): 7577–7582. PMID24605391.
- ^ abcDrug Enforcement Administration, Department of Justice (2015). 'Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Final order'. Federal Register. 80 (20): 5042–7. PMID25730924.
- ^ abcDrug Enforcement Administration (2015). 'Schedules of Controlled Substances: Extension of Temporary Placement of Three Synthetic Phenethylamines in Schedule I. Final order'. Fed. Regist. 80 (219): 70657–9. PMID26567439.
- ^'DEA Schedules Deadly Synthetic Drug U-47700'. November 10, 2016.
- ^Drug Enforcement Administration (2015). 'Schedules of Controlled Substances: Temporary Placement of Acetyl Fentanyl Into Schedule I. Final order'. Fed. Regist. 80 (137): 42381–5. PMID26189217.
- ^Drug Enforcement Administration, Department of Justice (2016). 'Schedules of Controlled Substances: Temporary Placement of Furanyl Fentanyl Into Schedule I. Final order'. Fed. Regist. 81 (229): 85873–7. PMID27906535.
- ^ abcdef'Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I'. Drug Enforcement Administration.
- ^Drug Enforcement Administration, Department of Justice (2017). 'Schedules of Controlled Substances: Temporary Placement of Acryl Fentanyl into Schedule I. Temporary scheduling order'. Federal Register. 82 (134): 32453–7. PMID28715161.
- ^ abcDrug Enforcement Administration, Department of Justice (2017). 'Schedules of Controlled Substances: Temporary Placement of ortho-Fluorofentanyl, Tetrahydrofuranyl Fentanyl, and Methoxyacetyl Fentanyl into Schedule I. Temporary amendment; temporary scheduling order'. Federal Register. 82 (206): 49504–8. PMID29091366.
- ^ abDrug Enforcement Administration, Department of Justice (2016). 'Schedules of Controlled Substances: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl into Schedule I. Final order'. Federal Register. 81 (92): 29492–6. PMID27192733.
- ^Drug Enforcement Administration, Department of Justice (2017). 'Schedules of Controlled Substances: Temporary Placement of 4-Fluoroisobutyryl Fentanyl into Schedule I. Temporary scheduling order'. Federal Register. 82 (84): 20544–8. PMID28497944.
- ^Drug Enforcement Administration, Department of Justice (2018). 'Schedules of Controlled Substances: Temporary Placement of Cyclopropyl Fentanyl in Schedule I. Temporary amendment; temporary scheduling order'. Federal Register. 83 (3): 469–72. PMID29319947.
- ^Drug Enforcement Administration, Department of Justice (2018). 'Schedules of Controlled Substances: Extension of Temporary Placement of MAB–CHMINACA in Schedule I of the Controlled Substances Act. Temporary rule; temporary scheduling order; extension'. Federal Register. 83 (20): 4411–2. PMID29461023.
- ^ abcdefgDrug Enforcement Administration, Department of Justice (2018). 'Schedules of Controlled Substances: Temporary Placement of Seven Fentanyl-Related Substances in Schedule I. Temporary amendment; temporary scheduling order'. Federal Register. 83 (22): 4580–5. PMID29932604.
- ^Drug Enforecement Administration, Department of Justice (2018). 'Schedules of Controlled Substances:Temporary Placement of Fentanyl-Related Substances in Schedule I. Temporary amendment; temporary scheduling order'. Federal Register. 83 (25): 5188–92. PMID29932611.
Abstract
The Biopharmaceutics Classification system (BCS) classifies drug substances based on aqueous solubility and intestinal permeability. The objective of this study was to use the World Health Organization Model List of Essential Medicines to determine the distribution of BCS Class 1, 2, 3, and 4 drugs in Abbreviated New drug Applications (ANDA) submissions. To categorize solubility and intestinal permeability properties of generic drugs under development, we used a list of 61 drugs which were classified as BCS 1, 2, 3, and 4 drugs with certainty in the World Health Organization Model List of Essential Medicines. Applying this list to evaluation of 263 ANDA approvals of BCS drugs during the period of 2000 to 2011 indicated 110 approvals (41.8%) for Class 1 drugs (based on both biowaiver and in vivo bioequivalence studies), 55 (20.9%) approvals for Class 2 drugs, 98 (37.3%) approvals for Class 3 drugs, and no (0%) approvals for Class 4 drugs. The present data indicated a trend of more ANDA approvals of BCS Class 1 drugs than Class 3 or Class 2 drugs. Antiallergic drugs in Class 1, drugs for pain relief in Class 2 and antidiabetic drugs in Class 3 have received the largest number of approvals during this period.
INTRODUCTION
The Biopharmaceutics Classification system (BCS) classifies drug substances based on aqueous solubility and intestinal permeability which are the major characteristics of a drug substance that control its absorption in vivo (). According to the BCS classification approach, drug substances have been grouped into one of the four categories as Class 1 (high solubility, high permeability), Class 2 (low solubility, high permeability), Class 3 (high solubility, low permeability), and Class 4 (low solubility and low permeability). The US Food and Drug Administration (US FDA) implemented guidance based on BCS to waive in vivo bioavailability and bioequivalence study requirements to approve drug products (2). Biowaivers can be granted if the active pharmaceutical ingredient (API) is BCS Class 1, i.e., a drug substance of high solubility and high permeability, and if the immediate-release (IR) oral formulation exhibits rapid in vitro dissolution (2). The BCS-based biowaiver approval has also been adopted by the European Medicines Agency and World Health Organization (WHO) for IR oral drug products (). The WHO guidance recommends biowaivers for APIs that belong to BCS Class 1 and Class 3 and also certain APIs from BCS Class 2 (4). It is important to emphasize that the US FDA considers granting biowaivers only for Class 1 drugs but does not use the WHO BCS Class 1 list to grant such biowaivers. Rather, the US FDA follows the criteria described in its Guidance for Industry on the BCS (2) and considers the applicant's submitted solubility/permeability data on API and dissolution data on the drug product in deciding whether a Class 1 biowaiver is appropriate.
An in vivo bioequivalence (BE) study is the accepted test to ensure therapeutic equivalence of a generic product to its corresponding reference product. The BCS-based BE study waiver is becoming an important tool in approving generic drug products by US FDA. Initially, BCS-based BE study waivers were granted only for Scale-Up and Post Approval Changes (5). Later, this was implemented to approve generic IR oral drug products of BCS Class 1 API. BCS biowaivers are not granted to drug products with a narrow therapeutic range and drug products designed to be absorbed in the oral cavity. In vivo bioequivalence study waivers help to avoid unnecessary human exposure to drugs. In addition, biowaivers reduce the cost and time of developing generic IR oral drug products and also decrease regulatory burden ().
In the present study, to gain an understanding of the solubility and intestinal permeability properties of generic drugs under development in the USA, we examined the distribution of BCS Class 1, 2, 3, and 4 drugs in ANDA submissions based on the WHO Model List of Essential Medicines (EML) having sufficient solubility and permeability data for BCS classification with certainty (). The WHO Model List of Essential Medicines was used merely to describe generic drug solubility and intestinal permeability properties because it is publicly available and includes BCS Class 1, 2, 3, and 4 designations. However, as stated previously, to determine whether a generic drug is eligible for a BCS biowaiver, the FDA follows its own criteria set forth in its BCS Guidance for Industry (2).
METHODS
An internal FDA database was applied to identify generic drugs approved during the 2000 to 2011 period. For determining the distribution of BCS Class 1, 2, 3, and 4 drugs in ANDA submissions, we used the approved generic drug products of immediate-release oral dosage forms listed on the WHO EML having sufficient solubility and permeability data for BCS classification with certainty.
RESULTS AND DISCUSSION
We evaluated 263 approved generic drugs of IR products listed on the WHO EML to find out the distribution of BCS Class 1, 2, 3, and 4 drugs in approved ANDA applications during the 2000 to 2011 period. The WHO EML was used as it is a publicly available list of Class 1, 2, 3, and 4 drugs. Some of the FDA-approved oral IR ANDA products which are not listed in the WHO EML could not be considered for the study mainly due to insufficient solubility and permeability data for BCS classification with certainty. Of the 130 orally administered drugs on the WHO EML, 61 drugs have been classified as BCS 1 (21 drugs), 2 (10 drugs), 3 (24 drugs), and 4 (6 drugs) drugs with certainty (). ANDA approval data from 2000 to 2011 were analyzed to determine how many BCS Class 1, 2, 3, and 4 drugs from the list of 61 drugs were developed and approved as generic drugs based on both BCS biowaivers (applicable only for Class 1) and BE studies. The results indicated 110 (41.8%) approvals for Class 1 drug products, 55 (20.9%) approvals for Class 2 drug products, and 98 (37.3%) approvals for Class 3 drug products (Fig. 1). Figure 2 shows the yearly approval of different BCS Class generic drug products during this period. There were no approvals for WHO EML BCS Class 4 drug products during the 2000 to 2011 period. Thirty two different therapeutic classes of IR products of BCS Class 1, 2, and 3 were approved during this period. Of these 32 different therapeutics classes, antiallergic drugs in Class 1, drugs for pain relief in Class 2, and antidiabetic drugs in Class 3 have received the largest number of approvals.
The percent approval of different classes of BCS drugs listed on WHO EML from 2000 to 2011
ANDA approvals of WHO EML BCS Class drug products from 2000 to 2011 based on BCS biowaivers and in vivo BE studies
As stated above, the US FDA grants biowaivers based on the applicant's submitted solubility/permeability data on API and dissolution data on the drug product. We evaluated the quality of BCS biowaiver ANDA applications submitted to the FDA and noted some commonly occurring deficiencies. These deficiencies are mostly associated with solubility and permeability studies on API and are listed below:
Lack of multi-pH solubility profiles
Inappropriate method of solubility determination
Lack of dissolution data for all strengths
Missing standard operating procedures for analytical methods
Missing data supporting gastrointestinal stability
Lack of data on efflux transporter(s) in the cell line used for in vitro permeability
Lack of bidirectional in vitro permeability data on control model compounds
2018 mp3 songs free download. The above information is provided to assist applicants who submit BCS biowaiver requests to the FDA to prepare high-quality submissions. We hope that publication of this information on commonly occurring deficiencies associated with BCS biowaiver ANDA applications will promote application and review efficiency.
CONCLUSION
The data presented in this study on 32 different therapeutic classes of BCS generic drugs approved by the US FDA during the 2000–2011 period indicated the following ANDA approval trend: BCS Class 1 > Class 3 > Class 2, with no BCS Class 4 drugs evaluated. Antiallergic drugs in Class 1, drugs for pain relief in Class 2, and antidiabetic drugs in Class 3 have received the largest number of approvals.